Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241358 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
A Phase 1 study of Multiple Myeloma and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT00241358: Completed Phase 1 study of Multiple Myeloma and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
NCT00241358 is a Phase 1 study of Multiple Myeloma and Myelodysplastic Syndromes that has completed, run by Washington University School of Medicine. The registered enrollment target is 92 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00241358, a Phase 1 study of Multiple Myeloma and Myelodysplastic Syndromes, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
Primary Outcome
-Defined as the proportion of donors collecting \>2.0x106 CD34+ cells/kg \[recipient weight\]
Conditions Studied
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG AMD3100
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2004-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
What the finished NCT00241358 record still lists
NCT00241358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (83% lower).
The record links to 8 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00241358 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT00241358 about?
NCT00241358 is a clinical study titled "Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies". The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
What is the current status of trial NCT00241358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2004-05. Estimated completion is 2010-02.
What conditions does trial NCT00241358 study?
This clinical trial studies the following conditions: Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Hodgkin Disease.
What interventions are being tested in trial NCT00241358?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), AMD3100 (DRUG).
Who is sponsoring clinical trial NCT00241358?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00241358 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00241358's enrollment target sits among peer trials
92 181st of 438 higher than 256 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia